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Osteopontin is a secreted, phosphorylated, acidic glycoprotein that was first identified in studies of 
bone repair but was subsequently shown to have mul-
tiple functions in the repair of other tissues, immune re-
sponses, and inflammation [1, 2]. In mineralized tissues, 
osteopontin binds to the extracellular matrix through in-
teractions between its asparagine-glycine-aspartate se-
quence and integrins, and it regulates calcium depo-
sition during the stress-induced remodeling of bone. 
In other tissues, osteopontin promotes wound heal-
ing and inhibits ectopic calcification [3–5]. Osteopon-
tin also functions in the induction of cellular and hu-
moral immune responses [6–8] and participates in both 
physiological inflammation during wound healing and 
immune responses and pathological inflammatory con-
ditions that include arthritides [9, 10], multiple sclerosis 
[11], and autoimmune diseases [8, 12, 13].
We recently found that osteopontin gene expres-
sion increased in HIV-1–infected lymphatic tissues af-
ter the institution of highly active antiretroviral ther-
apy (HAART) [14]. We provisionally interpreted this 
result as possible evidence of the wound-healing func-
tions of osteopontin (described above) in a previously 
unexamined tissue, but we sought further insight into 
osteopontin’s functions in the reparative response to 
HAART in lymphatic tissues by mapping the localiza-
tion of osteopontin. During the course of these studies, 
we discovered a previously unrecognized association 
of osteopontin with the follicular dendritic-cell (FDC) 
network of humans and primates but not that of mice, 
and we propose that this species-specific association re-
flects the evolution of osteopontin to facilitate antibody 
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Abstract
Osteopontin is a multifunctional protein with known roles in bone remodeling, wound healing, and normal and path-
ological immune responses. We showed in microarray studies that osteopontin gene expression is increased in hu-
man immunodeficiency virus type 1 (HIV-1)–infected lymphatic tissues after treatment, and we undertook mapping 
experiments to study osteopontin’s possible functions in this context. We discovered species-specific colocalization of 
osteopontin with the follicular dendritic cell (FDC) network in lymphatic tissues in HIV-1 and simian immunodefi-
ciency virus infections, and we found that changes in FDC-associated osteopontin covary with changes in lymphoid 
follicles during acute and late stages of infection and in response to treatment. We propose that this localization nor-
mally facilitates antibody production and plays a role in B cell abnormalities in infection and in the reconstitution of 
lymphoid follicles with treatment and that mapping genes identified in microarray studies is a useful experimental 
approach to gaining a better understanding of function in the context of a particular tissue and disease.
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production. In support of this hypothesis, we document 
(1) changes in FDC-associated osteopontin that parallel 
the well-known hypergammaglobulinemia and B cell 
abnormalities observed during the early stages of HIV-1 
and simian immunodeficiency virus (SIV) infections, (2) 
decreases in FDC-associated osteopontin that parallel 
the destruction of lymphoid follicles during late stages 
of infection, and (3) during HAART, a coordinate nor-
malization of follicular architecture and FDC-associated 
osteopontin.
Material and Methods
Human lymph-node biopsies. After we obtained signed, 
informed consent, inguinal lymph-node biopsies were 
performed, by use of standard surgical techniques, on 
individuals under local anesthesia who were partici-
pating in University of Minnesota institutional review 
board–approved protocols [15]. A portion of the tissue 
was placed in 4% paraformaldehyde for 3–4 h and was 
then transferred to 70% ethanol and embedded in par-
affin for in situ hybridization, immunohistochemical 
staining, and histological examination.
Lymph-node biopsies from SIV-infected rhesus ma-
caques. Axillary lymph-node biopsies were performed 
on adult female SIV- and simian retrovirus–negative 
rhesus macaques under anesthesia before and 1 and 4 
weeks after intravenous (iv) inoculation with 2 × 104 
ID50 of SIVmac239 (provided by R. Desrosiers, New 
England National Primate Research Center, Southbor-
ough, MA). All animal housing, care, and research were 
performed in accordance with the Guide for the Care and 
Use of Laboratory Animals [16] and with protocols ap-
proved by the Institutional Animal Care and Use Com-
mittee of the National Cancer Institute.
Immunohistochemical staining. For immunohisto-
chemical staining, after blocking to reduce nonspecific 
binding, sections were reacted sequentially with pri-
mary antibody, biotinylated secondary antibody, and 
ABC reagent, and then were stained with diaminoben-
zidine and counterstained with hematoxylineosin. For 
osteopontin staining, we used monoclonal antibod-
ies to human osteopontin peptides at the C terminus 3 
aa from the thrombin cleavage site (Immuno-Biological 
Laboratories), goat polyclonal antibodies to full-length 
recombinant mouse osteopontin (AF808; R&D Systems) 
and proteolytically derived Nand C-terminal fragments 
(provided by L. Fisher, National Institute of Dental and 
Craniofacial Research, National Institutes of Health, 
Bethesda, MD) [17, 18], rabbit polyclonal antibodies to 
full-length and N- and C-terminal fragments of recom-
binant mouse osteopontin (provided by L. Liaw, Maine 
Medical Center Research Institute, Scarborough, ME), 
and rabbit polyclonal antibodies that recognize full-
length and C-terminal fragments of osteopontin and 
cross-react with human, pig, and dog osteopontin (ab-
cam 8448; Novus Biologicals).
In situ hybridization. Tissue sections of 8 µm were 
cut and adhered to slides, deparaffinized, and subse-
quently pretreated for the detection of HIV RNA by 
in situ hybridization, as described elsewhere [19]. In 
brief, sections were pretreated with HCl, digitonin, and 
proteinase K, to enhance the diffusion of probes, and 
then acetylated, to reduce the nonspecific binding of 
probes. After the hybridization of a collection of 35S-la-
beled HIV-1–specific riboprobes, sections were washed, 
treated with ribonuclease, dehydrated, coated with 
NTB2 (Kodak), and developed and stained after radio-
autographic exposure. For osteopontin, cDNA from 
the American Type Culture Collection (ATCC number 
61052) was subcloned into the pBluescript II SK(-) plas-
mid, and an 35S-labeled riboprobe was prepared by in-
corporation of the label with T7 RNA polymerase.
Statistical analysis. A random-effects model was 
used to determine the statistical significance of changes 
in the percentage of FDC-associated osteopontin/lym-
phatic tissue area attributable to HAART. This analysis 
was necessary for combining information from 2 small, 
slightly different studies. The model assumed that the 
changes in each individual were normally distributed, 
given some study-specific mean effect, and that these 
study-specific mean effects were drawn from another 
normal distribution. The mean of the latter distribution 
was the estimate of the effect due to HAART. A Bayes-
ian approach was used, and computation was done by 
first integrating the variance parameters out of the pos-
terior distribution, then directly sampling the other 3 
parameters from a histogram approximation of their 
posterior distribution. Calculations were conducted by 
use of S-plus software (version 3.4; MathSoft).
Results
FDC-associated osteopontin in HIV-1–infected and –un-
infected lymphatic tissues as revealed by mapping stud-
ies. With the rationale that knowing where osteopontin 
was expressed in lymphatic tissues would provide ad-
ditional clues to its function, we determined sites of os-
teopontin expression by immunohistochemical staining. 
We had expected from the results of other studies [1, 20] 
that we would detect osteopontin in cells, but we had 
not seen a report of an association of osteopontin with 
lymphoid follicles. We were thus surprised to find that 
(1) before treatment, during the late stage of HIV-1 in-
fection, osteopontin colocalized with the FDC network 
in small residual secondary follicles; and (2) 2 months 
after the initiation of HAART, there was increased os-
teopontin staining in a pattern characteristic of the FDC 
network in the large follicles that had reformed by that 
time (Figure 1A and 1B). We confirmed the colocaliza-
tion of osteopontin protein with the FDC network by 
staining for the FDC marker CD35 and by revealing, 
through in situ hybridization, the virions bound to the 
FDC network [19] before treatment (Figure 1C and 1D). 
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Figure 1. Follicular den-
dritic cell (FDC)–associ-
ated osteopontin. 




with a monoclonal an-
tibody to a human os-
teopontin peptide at 
the C terminus in an 
HIV-1–infected in-
dividual in the late 
stages of infection be-
fore (A) and after (B) 
2 months of highly ac-
tive antiretroviral ther-
apy (HAART). Note 
the follicular pattern of 
staining and increased 
size of the follicle and 
osteopontin staining 
after HAART. 
C and D, Double-la-
bel in situ hybridiza-
tion to detect HIV-1 
RNA in virions bound 
to the FDC network 
and immunohisto-
chemical staining for 
osteopontin. 
C, Bright silver grains 
after in situ hybrid-
ization with 35S-la-
beled HIV-1–specific 





D, Double-label for 
CD35 to mark the 





E, Osteopontin staining 
at high magnification 
(×40) of the FDC net-
work in an HIV-1–un-
infected individual.
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We then investigated and documented osteopontin co-
locali zation with the FDC network in follicles in other 
HIV-1–infected and –uninfected individuals (Figure 1E).
Binding but not production of osteopontin by FDCs. 
Although the FDC network clearly binds osteopon-
tin, we did not detect osteopontin mRNA in FDCs by 
in situ hybridization, although we did detect osteo-
pontin mRNA (Figure 2A) in cells in the paracortical T 
cell zone identified by double-label staining as T cells 
and macrophages (Figure 2B and 2C).We conclude that 
these cells are the local source of osteopontin that binds 
to the FDC network.
Increase in FDC-associated osteopontin during 
HAART. We found that the size of the follicles and FDC-
associated osteopontin gene expression (Figure 1A and 
1B) increased in parallel, which suggests that follicle for-
mation and osteopontin synthesis and binding are con-
currently regulated. Because the FDC network is slowly 
reconstituted during HAART [21], we would there-
fore expect corresponding increases in FDC-associ-
ated osteopontin gene expression. We quantified FDC-
associated osteopontin as a percentage of the area of 
lymphatic tissues stained by antibody in a total of 12 
individuals in 2 separate studies over the course of 1.5 
years of HAART; indeed, we found, in a meta-analysis 
of the separate studies, statistically significant increases 
(P = .02) in FDC-associated osteopontin gene expres-
sion that closely matched the increases previously docu-
mented in the FDC network (data not shown) [21].
Increase in FDC-associated osteopontin gene expres-
sion during acute SIV infection. The increases in both 
osteopontin gene expression and the number and size 
of lymphoid follicles imply that FDC-bound osteopon-
tin gene expression should also increase with the well-
documented and particularly dramatic increases in the 
numbers and sizes of the follicles during the early stage 
of HIV-1 infection [22]. For obvious practical and ethi-
cal reasons, lymph-node biopsies cannot be obtained 
during the relevant time frame (before and shortly af-
ter HIV-1 infection) for testing this hypothesis. How-
ever, we were able to study lymph nodes obtained be-
fore and during acute SIV infection of rhesus macaques, 
a nonhuman primate model in which the changes in 
lymphatic tissues correspond closely to those in HIV-1 
Figure 2. A, Detection of osteopontin 
mRNA in cells in the paracortical T cell 
zone but not follicles. Brightly illuminated 
silver grains overlying cells but not 
follicles are evident in the section after 
in situ hybridization with HIV-1–specific 
35S-labeled riboprobes. B and C, Detection 
of osteopontin in T cells and macrophages. 
Arrows indicate doubly labeled T cells and 
macrophages, stained with anti-CD3 or 
anti-CD68, respectively, and osteopontin 
stained with the monoclonal antibody to 
the human osteopontin peptide described 
in the Figure 1 legend.
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Figure 3. Osteopontin in 
follicles and cells of a sim-
ian immunodeficiency vi-
rus (SIV)–infected rhesus 
macaque. 
A, Follicular dendritic cell–
associated osteopontin 
and 2 cells (arrow, inset). 
B, Increased osteopontin in 
follicles in early SIV in-
fection. Increased osteo-
pontin staining, using 
the monoclonal antibody 
to the human osteopon-
tin peptide described in 
the Figure 1 legend, par-
alleled the increased nos. 
and sizes of follicles in bi-
opsies from 3 macaques 
from baseline to 1 and 4 
weeks after intravenous 
infection.
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infection [23, 24]. Osteopontin colocalized to the rhe-
sus macaque FDC network (Figure 3A) and to cells in 
the paracortex (Figure 3A, inset); in accordance with the 
hypothesis, FDCbound osteopontin gene expression in-
creased substantially and proportionately with the in-
creased numbers and sizes of the follicles accompany-
ing immune activation in response to infection at 1 and 
4 weeks after IV infection with SIV (Figure 3).
No detection of FDC-associated osteopontin gene 
expression in the mouse. In addition to the follicular hy-
perplasia described above, polyclonal B cell activation 
and hypergammaglobulinemia are also characteristic 
of early HIV-1 infection [24–27]. Because the increased 
FDC-associated osteopontin gene expression observed 
in acute SIV infection pointed to a potential role of os-
teopontin in these B cell abnormalities that we could 
not directly test in fixed tissues, we designed experi-
ments with model antigens to examine the relationship 
between osteopontin gene expression and antibody 
production in mice. Because we had not seen descrip-
tions of osteopontin colocalizing with the FDC network 
in mice, and because of the many examples of differ-
ences in mouse and human immune systems [28], we 
first undertook some preliminary experiments to deter-
mine whether osteopontin was, in fact, associated with 
murine FDCs. Although the osteopontin antibodies 
readily detected osteopontin-positive cells in the para-
cortex and follicles (Figure 4) of mouse (B6 and other 
strains) lymph nodes, there was no detectable FDC-as-
sociated osteopontin in polyclonal and monoclonal an-
tibodies to full-length recombinant mouse osteopontin 
and proteolytically derived N- and C-terminal frag-
ments. Thus, osteopontin’s association with the FDC 
network is species specific.
Discussion
In the present studies, we found that (1) there is a species-
specific association of osteopontin with the FDC network 
and (2) changes in the levels of FDC-associated osteo-
pontin gene expression are correlated with pathologi-
cal abnormalities in lymphoid follicles in HIV-1 and SIV 
Figure 4. Osteopontin-positive cells but no follicular dendritic cell (FDC)–associated osteopontin in sections from a B6 mouse 
lymph node. Osteopontin was detected with rabbit polyclonal antibody to a 32-KDa C-terminal fragment of recombinant mouse 
osteopontin. Arrows indicate osteopontin-positive cells in the encircled follicle with no detectable staining of the FDC network.
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infections and the reparative response to HAART. We 
now discuss what these findings might imply about FDC-
associated osteopontin’s roles, both normally in antibody 
production and in immunodeficiency virus infections.
The association of osteopontin with the FDC network 
locates a powerful antibody-stimulating cytokine in the 
lymphoid follicle structure, which is organized to bring 
together antigen bound to the FDC network, B cells, and 
germinal-center CD4+ cells to stimulate B cell prolifera-
tion and differentiation for the production of high-affin-
ity antibodies. The FDC-associated osteopontin could be 
contributing to antibody production at this site by facil-
itating FDC–CD4+ cell germinal-center interactions that 
augment Th1 cytokine and CD40L expression. Because 
osteopontin is known to augment CD40L expression in 
T cells [32], FDC-associated osteopontin is ideally sited 
anatomically to increase the expression of CD40L on 
CD4+ cells in close proximity to B cells, thereby induc-
ing B cell proliferation and antibody production.
Osteopontin in mice, similarly, has long been known 
to stimulate antibody production and B cell prolifera-
tion through CD40-CD40L and other interactions with 
CD4+ cells. T cells and macrophages also produce osteo-
pontin in mice, just as we have shown in humans and 
nonhuman primates. However, osteopontin was not de-
tectably bound by FDCs in mice, in contrast to what was 
seen in primate species. Although the murine and hu-
man osteopontin sequences are closely related [33–35], 
we conclude from the present studies that the additional 
sequences that osteopontin has acquired through evolu-
tion enable it to bind to FDCs for the facilitation of anti-
body production.
In all 3 species, elevated levels of osteopontin were 
implicated in B cell abnormalities. In mice, high levels of 
osteopontin were associated with polyclonal B cell acti-
vation, autoimmune disease, and murine AIDS, respec-
tively, in MRL/lpr mice, osteopontintransgenic mice, 
and mice infected with the retrovirus LP-BM5 [8, 12, 13, 
20]. In human and nonhuman primate lymphatic tis-
sues, changes in the levels of FDC-associated osteopon-
tin that could be contributing to the B cell abnormalities 
observed in HIV-1 and SIV infections and to the patho-
logical changes in lymphoid follicles in these infections 
that cover a spectrum from follicular hyperplasia, to in-
volution, to the development of lymphomas [22, 29]. 
During the early stages of infection, the deposition of vi-
ral immune complexes in the FDC network is associated 
with increases in the number and size of the follicles 
and with the concomitant generalized polyclonal activa-
tion of B cells that results in hypergammaglobulinemia 
[24, 26, 27, 30]. Recent evidence has suggested that hy-
peractivated naive B cells are responsible for increased 
immunoglobulin production [31] and that the abnormal 
differentiation of naive B cells is driven by CD40-CD40L 
interactions that would be enhanced by FDCassociated 
osteopontin gene expression.
By the later stages of infection, HIV-1 and SIV have 
destroyed lymphoid follicles, with accompanying de-
fects in the humoral immune response to recall antigens 
and vaccination that reflect structural damage and re-
ductions in the number of memory B cells [31]. We had 
shown previously that this destructive process is revers-
ible by HAART. During HAART, follicles reformed over 
a period from a few months to 1.5 years of treatment; by 
the latter time point, levels were similar in proportion 
to numbers of follicles in HIV-1–uninfected individuals 
[36]. Here, we have provided encouraging evidence that 
the capacity to regenerate FDC-associated osteopontin is 
retained as another component of the immune reconsti-
tution that takes place during HAART.
Finally, the present studies illustrate how mapping 
the cellular and anatomic location of genes discov-
ered in microarray studies can help define function in 
a particular tissue and disease. In particular, in the im-
munodeficiency virus infection of lymphatic tissues, 
there would have been no a priori reason or literature 
on osteopontin to suspect binding to FDCs and, there-
fore, a potentially new role in normal and abnormal B 
cell states. Thus, mapping studies can complement gene 
profiling by pointing the way forward from hypothesis 
generation to hypothesis testing.
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